Olvera OK, Fernández CE, Gómez ME, Sánchez VE, Morales PM, Murillo E

Language: Spanish
References: 7
Page: 186-191
PDF size: 120.16 Kb.

ABSTRACT

Hematopoietic stem cell transplantation is a healing option for lethal diseases. Even though mortality and morbidity have diminished, transplant has a toxicity risk ranging from 5-20%, due to conditioning regimen; which is higher in allotransplant. Many strategies have been used to prevent toxicity to different organs, being the appropriate management of such toxic effects the only strategy that can modify the course to survival, recovery or death. Objective: To evaluate the effectiveness of the toxicity prophylaxis protocol due to conditioning regimen in adult patients subjected to transplantation. Methods: The same toxicity prophylaxis protocol was applied to 21 patients subjected to transplantation during hospitalization. Modifications to the protocol were identified according to clinical or laboratory variables. Efficacy was stated if toxicity was = grade III; measured on days 0,7,14 and 28 according to WHO and Bearman scales. Results: Twenty one patients were included since 2002: 10 male and 11 female, ages between 17 and 62. In the registered modifications to protocol, the gastrointestinal predominated in 16 patients; 14 due to stomatitis, 5 to hepatitis. Prophylaxis protocol was 100% effective for heart, bladder, kidney and central nervous system toxicity. Conclusions: Toxicity to mucosae is the most common adverse effect related to conditioning regimen, followed by gastrointestinal toxicity; which indicates that a modification to the protocol is necessary in these areas. WHO and Bearman scales are useful instruments in decision making regarding pharmacological management in the patient subjected to transplantation.

REFERENCES

1. Bearman et al. Regimen-related toxicity in patients undergoing bone marrow transplantation. J Clinic Oncol 1988; 6: 1562-1568.

2. Bearman et al. Regimen-related toxicity and early post transplant survival in patients undergoing allogeneic marrow transplantation. J Clin Oncol 1989; 7: 1288-1294.

3. Pallera AM., Schwartzberg LS. Managing the toxicity of hematopoietic stem cell transplant. J Support Oncol 2004; 2 (3): 223-237.

4. Krouwer H. Neurologic complication of bone marrow transplantation. Neurol Clin 2003; 21 (1): 319-352.

5. Petersen FB, Bearman SI. Preparative regimens and their toxicities. In: Forman SJ, Blume KG, Thomas ED (eds). Bone Marrow Transplantation. Cambridge, Mass: Blackwell Scientific Publications, 1993. pp 79-91 .

6. Reyli C. Drugs facts and comparisons. 57th ed. Kansas University Medical Center. Kansas City: Wolters Kluwer Health, 1302.7. B.C. Cancer Agency care and research: www.bccancer.bc.ca/HPI/DrugDatabase/DrugIndexPt/Fludarabineinjection.htm

7. Moulder JE. ACE inhibitors and All receptor antagonists in treatment and prevention of bone marrow transplantation. Curr Pharm Des 2003; 9: 737-749.